Publication details
Voriconazole pharmacokinetic models - comparing two softwares
| Authors | |
|---|---|
| Year of publication | 2024 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Voriconazole (VRC), a second-generation azole antifungal, is the first choice for the treatment of Aspergillus infections. VRC is a drug with significant intra- and inter-individual variability, therapeutic monitoring (TDM) of voriconazole is therefore recommended for most patients according to currently valid international standards. However, the full potential of TDM in clinical practice can be exploited based on pharmacokinetic models with high predictive power that are not currently available for specific patient populations. The aim is to compare two pharmacokinetic models in the context of measured plasma concentrations of VRC in real patients. |
| Related projects: |